

L5 ANSWER 3 OF 3 DGENE (C) 2003 THOMSON DERWENT
 AN AAT88163 cDNA to mRNA DGENE
 TI Erythroid Differentiation inducing Activity, EDA, protein - useful to treat disease associated with disorders in differentiation inducing activity of erythropoietic cells
 IN Doermer P
 PA (GSFU-N) GSF-FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GmbH.
 PI DE 19612463 A1 19971002 38p
 AI DE 1996-19612463 19960328
 PRAI DE 1996-19612463 19960328
 PSL Claim 12; Pages 14-15
 DED 20 APR 1998 (first entry)
 DT Patent
 LA German
 OS 1997-481697 [45]
 DESC cDNA generated from leukaemic myelomonocyte cell line WEHI-3.
 KW Murine; leukaemic myelomonocyte cell line; WEHI-3; ATCC TIB68; DY-8; erythroid differentiation inducing activity; eda; treatment; disease; disorder; erythropoietic cell; inhibitor; antibody; antisense oligonucleotide; therapy; diagnosis; research; probe; ss.
 ORGN Mus musculus.
 AB **AAT88163**, a consensus partial sequence of a 2200 bp cDNA molecule generated from a murine leukaemic myelomonocyte cell line WEHI-3
 (ATCC TIB68) mRNA, has no continuous open reading frames (ORF) and may lack internal sections. AAV04410 is that of another WEHI-3 cDNA clone called DY-8, and contains 640 bp of the 3' region of the erythroid differentiation inducing activity (eda) gene and includes an ORF encoding
 AAW27721. A novel differentiation inducing protein can be isolated from murine leukaemic myelomonocyte cell lines or irradiated human bone marrow
 stroma cells, induces differentiation in Friend erythroleukaemia cells resulting in haemoglobin formation, has a molecular weight of 10-60 kD and is inducible by a serum factor present in foetal calf serum. Its corresponding mRNA is expressed in primary cells from thymus, foetal liver, adult spleen or bone marrow and is stably expressed in vitro when an allogeneic spleen cell reaction is performed with non-irradiated, non-pretreated spleen cells from mouse strains CBA and C57B16. Its corresponding cDNA has characteristic repeat structures and AT rich regions, and species of its corresponding mRNA of different sizes have the same 3' region but different 5' regions. The protein can be used to treat diseases associated with disorders in the differentiation inducing activity of erythropoietic cells. It, or an inhibitor, e.g. an antibody or antisense oligonucleotide, can also be used to treat diseases in which
 local or systemic over or under production of the protein has an influence on the development or progression of disease. A hybrid of the nucleic acid sequence encoding it can be used for therapeutic, diagnostic
 or research purposes, especially as a molecular probe or antisense molecule to inhibit gene expression.
 NA 305 A; 397 C; 390 G; 403 T; 0 other
 SQL 1495
 SEQ
 1 ccgaccgtgc ggacttaaga tggaggcact tctgtctgc ggcgggaaga
 51 gaaggctcgg tcggagccgg gaatgctggg acttgtagtg cgtagtcaat

101	ggttctctat	gggctttcag	agtgagtggc	gggaaggcgg	ccccgaggca
151	tgctgggagt	tgtagtcctg	ccgtcgtcaa	tggttctcta	tgggctttca
201	gagtgagtgg	cgggaaggcg	gccccgaggc	atgctgggag	ttgtagtcct
251	gccatagtca	atggttctct	atgggctttc	agactgagtg	gcgggaaggc
301	ggccccgagg	catgctggga	gttgacgcgc	catgttttaa	agcacgcgtt
351	tctctgtata	gacctggctg	tggatttttc	gctaattcct	tttttttagct
401	ttatttttaa	tttttacttt	ttcacacagg	atttctcttt	atagccttgg
451	ctaccgtttt	ttccctaatt	attctccttt	tcatttttgg	ttattttttt
501	ttaatttttg	tttttttaag	acagggtttc	tctgtataga	cctggctgtg
551	gattttctcac	taattatttt	tttttagctt	atttttaatt	tttacttttt
601	cacacaggat	ttctctttat	agccttggct	accgtttttt	ccgtaattat
651	tcttattttt	atttttgggt	attttttaat	tttaattttt	gatttttgag
701	acaggggttc	tcttttagcc	gcagctatgg	tttctgcctt	aattattcct
751	gtccttattt	gtaatttaat	tcttaattta	atttaattta	taattttgtt
801	gtaagttttt	ctgtgggcgt	gaatggaaag	tctaaccctg	gtttctctgt
851	tcagcgtccg	ccggtcacgg	ccgccgcccc	cagcgacgtc	acccacacgc
901	gcagaagcgg	acgccgcggt	caagatgtct	ctgccatgcc	cacgggacgc
951	acggacgcac	ggacggacgg	acggactcca	caaggtagga	agcctgcgcc
1001	gaccgcaccg	ccgcacccac	cacagcacac	aggacacacg	cgggccccgc
1051	gccccgccag	gcacacgcgg	cacacacggc	acacacggca	ggcaggccag
1101	gcacacgcat	ccgcaggacc	cgccgcaccc	gccacgcaga	cacggacgag
1151	ccgccgcggt	caagatgttc	acccgccgcg	gtcaagatgt	atgtgccacc
1201	gaccctcgcc	ccgctggacg	gacggacgga	cgcacgcacg	ccgtcagcgt
1251	ccaccggtca	ctgccgccgc	ccacagtgat	gtcaccacacg	aaagcacaca
1301	cgtagaagcg	gacgccgtgg	tcaagatgtc	tctgccatcc	ccacaggacg
1351	gacggacgga	ctccacaagg	tgcgcgtgtc	gccgaggccg	ccaggacgga
1401	gcgattctca	cggaggaagg	agcacgccaa	cagggcctga	ctgcgtacag
1451	acatgtcccc	ctcaataaaa	ttgcagttga	aatggaaaaa	aaaaa

L5 ANSWER 2 OF 3 DGENE (C) 2003 THOMSON DERWENT
 AN AAV04410 DNA DGENE
 TI Erythroid Differentiation inducing Activity, EDA, protein - useful to treat disease associated with disorders in differentiation inducing activity of erythropoietic cells
 IN Doermer P
 PA (GSFU-N) GSF-FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GmbH.
 PI DE 19612463 A1 19971002 38p
 AI DE 1996-19612463 19960328
 PRAI DE 1996-19612463 19960328
 PSL Claim 12; Pages 15-16
 DED 20 APR 1998 (first entry)
 DT Patent
 LA German
 OS 1997-481697 [45]
 CR P-PSDB: AAW27721
 DESC cDNA generated from leukaemic myelomonocyte cell line WEHI-3.
 KW Murine; leukaemic myelomonocyte cell line; WEHI-3; ATCC TIB68; DY-8; erythroid differentiation inducing activity; eda; treatment; disease; disorder; erythropoietic cell; inhibitor; antibody; antisense oligonucleotide; therapy; diagnosis; research; probe; ss.
 ORGN Mus musculus.
 AB **AAT88163**, a consensus partial sequence of a 2200 bp cDNA molecule generated from a murine leukaemic myelomonocyte cell line WEHI-3
 (ATCC TIB68) mRNA, has no continuous open reading frames (ORF) and may lack internal sections. AAV04410 is that of another WEHI-3 cDNA clone called DY-8, and contains 640 bp of the 3' region of the erythroid differentiation inducing activity (eda) gene and includes an ORF encoding
 AAW27721. A novel differentiation inducing protein can be isolated from murine leukaemic myelomonocyte cell lines or irradiated human bone marrow
 stroma cells, induces differentiation in Friend erythroleukaemia cells resulting in haemoglobin formation, has a molecular weight of 10-60 kD and is inducible by a serum factor present in foetal calf serum. Its corresponding mRNA is expressed in primary cells from thymus, foetal liver, adult spleen or bone marrow and is stably expressed in vitro when an allogeneic spleen cell reaction is performed with non-irradiated, non-pretreated spleen cells from mouse strains CBA and C57B16. Its corresponding cDNA has characteristic repeat structures and AT rich regions, and species of its corresponding mRNA of different sizes have the same 3' region but different 5' regions. The protein can be used to treat diseases associated with disorders in the differentiation inducing activity of erythropoietic cells. It, or an inhibitor, e.g. an antibody or antisense oligonucleotide, can also be used to treat diseases in which
 local or systemic over or under production of the protein has an influence on the development or progression of disease. A hybrid of the nucleic acid sequence encoding it can be used for therapeutic, diagnostic
 or research purposes, especially as a molecular probe or antisense molecule to inhibit gene expression.
 NA 157 A; 285 C; 212 G; 61 T; 0 other
 SQL 715
 SEQ
 1 cgcgccccgcc cgggatcccc agctgccgcc gcgccccgcc gcccgccccg

```

51 ggcccccgct gcagaaccgt gaccgtccgc cggtcacggc cgccgcccc
101 agcgacgtca cccacacgcg cagaagcgga cgccgcggtc aagatgtctc
151 tgccatgccc acgggacgca cggacgcacg gacggacgga cggactccac
201 aaggtaggaa gcctgcgccg accgcaccgc cgcacccacc acagcacaca
251 ggacacacgc gggccccgcg cccgcccagg cacacgcggc acacacggca
301 cacacggcag gcaggccagg cacacgcac cgcaggaccc gccgcacccg
351 ccacgcagac acggacgagc cgccgcggtc aagatgttca cccgcccgcg
401 tcaagatgta tgtgccaccg accctcgccc cgctggacgg acggacggac
451 gcgcgcacgc cgtcagcgtc caccggtcac tgccgccgcc cacagtgatg
501 tcaccacga aagcacacac gtagaagcgg acgccgtggt caagatgtct
551 ctgccatccc cacaggacgg acggacggac tccacaaggt gcgcgtgtcg
601 ccgaggccgc caggacggag cgattctcac ggaggaagga gcacgccaac
651 agggcctgac tgcgtacaga aatgcccccc ctcaataaaa ttgcagttga
701 aatggaaaaa aaaaa

```

FEATURE TABLE:

Key	Location	Qualifier
CDS	155..688	*tag= a

LS ANSWER 1 OF 3 DGENE (C) 2003 THOMSON DERWENT
 AN AAW27721 Protein DGENE
 TI Erythroid Differentiation inducing Activity, EDA, protein - useful to
 treat disease associated with disorders in differentiation inducing
 activity of erythropoietic cells
 IN Doermer P
 PA (GSFU-N) GSF-FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GmbH.
 PI DE 19612463 A1 19971002 38p
 AI DE 1996-19612463 19960328
 PRAI DE 1996-19612463 19960328
 PSL Claim 5; Pages 16-17
 DED 20 APR 1998 (first entry)
 DT Patent
 LA German
 OS 1997-481697 [45]
 CR N-PSDB: AAV04410
 DESC Murine erythroid differentiation inducing activity protein.
 KW Murine; leukaemic myelomonocyte cell line; WEHI-3; ATCC TIB68; DY-8;
 erythroid differentiation inducing activity; eda; treatment; disease;
 disorder; erythropoietic cell; inhibitor; antibody; antisense
 oligonucleotide; therapy; diagnosis; research; probe.
 ORGN Mus musculus.
 AB **AAT88163**, a consensus partial sequence of a 2200 bp cDNA
 molecule generated from a murine leukaemic myelomonocyte cell line
 WEHI-3
 (ATCC TIB68) mRNA, has no continuous open reading frames (ORF) and may
 lack internal sections. AAV04410 is that of another WEHI-3 cDNA clone
 called DY-8, and contains 640 bp of the 3' region of the erythroid
 differentiation inducing activity (eda) gene and includes an ORF
 encoding
 AAW27721. A novel differentiation inducing protein can be isolated from
 murine leukaemic myelomonocyte cell lines or irradiated human bone
 marrow
 stroma cells, induces differentiation in Friend erythroleukaemia cells
 resulting in haemoglobin formation, has a molecular weight of 10-60 kD
 and is inducible by a serum factor present in foetal calf serum. Its
 corresponding mRNA is expressed in primary cells from thymus, foetal
 liver, adult spleen or bone marrow and is stably expressed in vitro when
 an allogeneic spleen cell reaction is performed with non-irradiated,
 non-pretreated spleen cells from mouse strains CBA and C57Bl6. Its
 corresponding cDNA has characteristic repeat structures and AT rich
 regions, and species of its corresponding mRNA of different sizes have
 the same 3' region but different 5' regions. The protein can be used to
 treat diseases associated with disorders in the differentiation inducing
 activity of erythropoietic cells. It, or an inhibitor, e.g. an antibody
 or antisense oligonucleotide, can also be used to treat diseases in
 which
 local or systemic over or under production of the protein has an
 influence on the development or progression of disease. A hybrid of the
 nucleic acid sequence encoding it can be used for therapeutic,
 diagnostic
 or research purposes, especially as a molecular probe or antisense
 molecule to inhibit gene expression.
 AA 22 A; 29 R; 1 N; 9 D; 0 B; 4 C; 12 Q; 4 E; 0 Z; 13 G; 12 H; 1 I;
 3 L; 2 K; 3 M; 0 F; 23 P; 9 S; 22 T; 1 W; 1 Y; 6 V; 0 Others
 SQL 177

SEQ

```
    1 mptgrtdart dgrtpqgrkp aptapphppq htghtraprp prhtrhtrht  
   51 rqagqahasa gpaapatqtr tsrrgqdvhp prsrcmchrp sprwtdgrtr  
  101 arrqrppvta aahsdvthes thveadavvk mslpspqdgr tdstrcacrr  
  151 grqdgailte egarqqglt a yrnappq
```